AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) has received approval from ...
The FDA has approved Enhertu (fam-trastuzumab deruxtecan-nxki) for HR-positive, HER2-low or HER2-ultralow metastatic breast cancer.
AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, ...
This study presents a valuable finding on the alterations in the autophagic-lysosomal pathway in a Huntington's disease model. The evidence supporting the claims of the authors is solid. However, the ...
Light and electron microscopy have distinct limitations. Light microscopy makes it difficult to resolve smaller and smaller ...
A new imaging technique reveals ribosomes work together when translating mRNA, preventing slowdowns in protein production. This discovery challenges prior beliefs and could revolutionize our ...
A research group at Umeå University has developed new advanced light-controlled tools that enable precise control of proteins ...
Light and electron microscopy have distinct limitations. Light microscopy makes it difficult to resolve smaller and smaller features, and electron microscopy resolves small structures, but samples ...
This study presents fundamental insights into overcoming resistance in hormone receptor-positive breast cancer by demonstrating that sustained CDK4/6 inhibitor treatment, either alone or in ...
Membrane biophysics is the study of the physical ... and the effect they have on paracellular transport and phenomena relating to cell shape. The mechanism of RCD-1 regulated cell death in fungal ...
Moreover, staining of adjacent inflamed PsA synovium with antibodies to RANKL revealed intense expression by the synovial lining cells, while osteoprotegerin staining was relatively faint and limited ...
WILMINGTON, Del., December 05, 2024--AstraZeneca’s IMFINZI® (durvalumab) has been approved in the US for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC ...